The battle between over-the-counter generic and branded drugs is going from the pharmacy aisles to the Internet.

Recently, generic-drug specialist Perrigo (NYSE:PRGO) announced a marketing campaign aimed at educating consumers and explaining the advantages that generic over-the-counter products have over their branded, more expensive counterparts. Will this strategy immediately grow the company's revenue? Conversely, does this spell doom for branded drugmakers such as Merck (NYSE:MRK) orĀ Pfizer? Health-care analyst Max Macaluso discusses these topics in the following video.

Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.